- Home
- SKY vs AKRO Comparison
SKY vs AKRO Comparison
Compare SKY & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKY
- AKRO
- Stock Information
- Founded
- SKY 2010
- AKRO 2017
- Country
- SKY United States
- AKRO United States
- Employees
- SKY N/A
- AKRO N/A
- Industry
- SKY Homebuilding
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- SKY Consumer Discretionary
- AKRO Health Care
- Exchange
- SKY Nasdaq
- AKRO Nasdaq
- Market Cap
- SKY 3.6B
- AKRO 3.7B
- IPO Year
- SKY N/A
- AKRO 2019
- Fundamental
- Price
- SKY $82.95
- AKRO $54.00
- Analyst Decision
- SKY Buy
- AKRO Buy
- Analyst Count
- SKY 2
- AKRO 10
- Target Price
- SKY $85.00
- AKRO $73.56
- AVG Volume (30 Days)
- SKY 847.9K
- AKRO 2.0M
- Earning Date
- SKY 11-04-2025
- AKRO 11-07-2025
- Dividend Yield
- SKY N/A
- AKRO N/A
- EPS Growth
- SKY 48.48
- AKRO N/A
- EPS
- SKY 3.84
- AKRO N/A
- Revenue
- SKY $2,624,539,000.00
- AKRO N/A
- Revenue This Year
- SKY $5.10
- AKRO N/A
- Revenue Next Year
- SKY $4.21
- AKRO N/A
- P/E Ratio
- SKY $21.50
- AKRO N/A
- Revenue Growth
- SKY 12.14
- AKRO N/A
- 52 Week Low
- SKY $59.44
- AKRO $21.34
- 52 Week High
- SKY $116.49
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- SKY 64.83
- AKRO 67.29
- Support Level
- SKY $64.45
- AKRO $53.90
- Resistance Level
- SKY $68.44
- AKRO $54.31
- Average True Range (ATR)
- SKY 3.46
- AKRO 0.23
- MACD
- SKY 1.09
- AKRO -0.25
- Stochastic Oscillator
- SKY 98.77
- AKRO 66.30
About SKY Skyline Champion Corporation
Champion Homes Inc is a factory-built housing company in North America. The company is well positioned with an portfolio of manufactured and modular homes, ADUs, park-models and modular buildings for the single-family, multi-family, and other hospitality sectors. In addition to its core home building business, the company provides construction services to install and set-up factory-built homes, operates a factory-direct retail business with 72 retail locations across the United States, and operates Star Fleet Trucking, providing transportation services to the manufactured housing and other industries from several dispatch locations across the United States.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.